Drug Recall: Duloxetine Tablets (Cymbalta generic) by Breckenridge
Breckenridge is recalling more than 12,000
30-count bottles of duloxetine delayed release, 40mg tablets due
to the presence of nitrosamine impurities above FDA recommended
limit.
Nitrosamine impurities can increase risk of cancer. The drug
is manufactured by Towa Pharmaceuticals in Barcelona, Spain.
Duloxetine is generic for Cymbalta and treats depression. The FDA classified the recall
as class II on July
30, 2025. Breckenridge issued a
larger recall,, for over 343,000 bottles, for other lots and
strengths of this drug April 2025. Check the enforcement report
for specific lot numbers and expiration dates.
Recall Announcement
Read or add patient reviews of Duloxetine or Cymbalta.
Drug Recall: Rizatriptan Tablets by Ascend
Ascend Laboratories is recalling 5mg and
10mg strength rizatriptan tablets due to the presence of
nitrosamine impurities.
Nitrosamine impurities can increase risk of cancer. The
quantity is not listed in the recall announcement. The drug is manufactured in India by Alkem Laboratories Ltd. Rizatriptan is
generic for migraine headache drug Maxalt. The FDA classified the
recall as class II on July 17, 2025.
Recall Announcement
Drug Recall: Lisdexamfetamine (Vyvanse generic) Capsules by Sun Pharma
Sun Pharmaceuticals is recalling 5,488 bottles of 100-count lisdexamfetamine dimesylate 60 mg capsules due to “failed dissolution specifications,” or problems with long-term (9 month) stability. The capsules are manufactured in New Brunswick, NJ by OHM Labs for distribution by Sun Pharma. The recalled units were sent to 17 distributors who may have further distributed the product nationwide. Lisdexamfetamine is a stimulant and also sold as an ADHD treatment under the brand names Vyvanse and Elvanse. The recall was initiated on June 16 and classified as a Class II recall on July 11, 2025. Lisdexamfetamine comes in strength from 10 mg to 60 mg.
Note: FDA and an
investigative report by Propublica have found violations at
Sun Pharma’s Indian-based facilities recently. This facility for
lisdexamfetamine is in the U.S. 
Recall Announcement
(enforcement report)
Read or add patient reviews for
Vyvanse
Drug Recall: Budesonide by Cipla
Cipla USA is recalling 13,680 ampoules of
budesonide (an asthma treatment) due to lack of assurance of
sterility. Some complaints have been received for leaky and/or
empty ampoules. The
medication is manufactured in Pithampur, Idia by Cipla Ltd.
Recall Initiation Date was June 30, 2025 and the FDA classified
it as a Class II recall on July 22, 2025. This medication is
administered by administered via jet nebulizer. Budesonide is
generic for Pulmicort.
Recall Announcement
Drug Recall: Omeprazole by Dr. Reddy's
Dr. Reddy’s Laboratories is recalling 1,476
bottles of its omeprazole delayed-release capsules due to the “presence
of foreign tablets/capsules” within the Omeprazole bottles.
Divalproex Sodium extended-release 250 mg tablets were
found mixed in with the Omeprazole capsules. The capsules are manufactured at Dr. Reddy’s Bachupally India plant. The recall
was initiated June 30, 2025 and classified as a Class 2 Recall on
July 14, 2025. Omeprazole is used to treat acid reflux,GERD, and
ulcers.
Recall Announcement
Drug Recall: Timolol Maleate Ophthalmic Eye Drops by FDC Ltd. (Rising Sun Pharma) and Apotex
FDC Limited is recalling 154,176 5 ml bottles and more than 60,428 10 ml bottles of .5% timolol maleate Ophthalmic eye drops made by FDC Limited in Aurangabad, Maharashtra, India due to a detective cap and container. The spike of the cap may be lodged in the nozzle of the product bottle. This medication is used to treat glaucoma. It is distributed by Rising Sun Pharmaceuticals. The recall was initiated in April and June and July 2025 and classified as a class II recall.
Recall Announcement (for the 154K recall); and Recall Announcement for the 60K recall
Read or add reviews for Timolol Maleate.
Apotex is
recalling more than 6,000 bottles of Brimonidine Tartrate/Timolol Maleate
Ophthalmic Solution, 0.2%/0.5%, 15 mL The drops are manufactured by:
Apotex Inc., Toronto, Ontario, Canada due to lack of sterility. Classified as
Class II recall on June 25, 2025.
Recall
Announcement for Apotex
Drug Recall: Clomipramine Hydrochloride by Lupin
Lupin Pharmaceuticals Inc. is recalling 2,724 bottles of 100-count
clomipramine hydrochloride Capsules due to a failed degradation product test
near the product expiration date. It is not known where the medication was
manufactured. The recall was initiated on June 27 and classified by the fda on
7/21/2025. Clomipramine is a dibenzazepine drug also known as tricyclic
antidepressant and is often used to treat obsessive-compulsive-disorder (OCD).
Its brand name is Anafranil.
Recall Announcement
Drug Recall: Cinacalcet Tablets by Stride Pharma
Strides Pharma is recalling 6,200 bottles of 30-count 90 mg cinacalcet tablets
due to failed dissolution specifications. This means that the drug may not be
absorbed in the body enough to be effective. Cinacalcet is the generic version
of Sensipar, a treatment for secondary hyperparathyroidism (HPT) in adult
patients with chronic kidney disease (CKD) on dialysis The product is manufactured by Strides Pharma Science Limited in Puducherry, India. The recall was classified as a Class II recall on July 30, 2025.
Recall Announcement
Note: product images are from the National Library of Medicine's DailyMed database. Recall information is linked and is from FDA Enforcement Reports.
Check out our other recent list of recalls, including Sucralfate, Levothyroxine, and Gabapentin.